Improving the mda-7/IL-24 refolding and purification process using optimized culture conditions based on the structure characteristics of inclusion bodies

Abstract

Background

The melanoma differentiation-associated gene-7 (mda-7)/interleukin-24 (IL-24) can induce apoptosis in a wide variety of tumor cell types, whereas it has no toxicity in normal cells. However, recombinant human mda-7/IL-24 is difficult to obtain from Escherichia coli because of its insolubility.

Results

In this study, we improved the structure of inclusion bodies (IBs) by optimizing the induction temperature, pH, concentrations of inducer, and metal ion additives. Statistically designed experimental analyses of three metal ion factors were performed using the Box-Behnken design. Induction temperature of 30°C, pH 7.0, and 0.1 mM isopropyl-β-d-thiogalactopyranoside (IPTG) were selected, and the optimized levels for the factors predicted by the model comprised the following: Mg²⁺ (15.7 mM), Ca²⁺ (16.6 mM), and Mn²⁺ (3.0 mM). The optimized culture conditions improved the structure of the IBs, which was validated by scanning electron microscopy (SEM) and the increase of IBs solubility.

Conclusions

After optimization, IB solubility and renatured mda-7/IL-24 increased by 51% and 84%, respectively. This study also provided a simple purification method of specific IB washing steps. Manipulating the fermentation parameters to optimize the refolding and purification process is likely to be widely applicable to other proteins.

Keywords

Escherichia coli / Expression / Inclusion body / Interleukin-24 / Purification / Refolding

References

[1.] Fisher PB. Is mda-7/IL-24 a “magic bullet” for cancer?. Cancer Res, 2005, 65: 10128-10138.

[2.] Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene, 1995, 11: 2477-2486.

[3.] Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH, Retter MW, Hill P, Chada S, Grimm EA. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol, 2002, 168: 6041-6046.

[4.] Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB, Leitner WW, Yang HY, Sahin AA, Hunt KK, Fuson KL, Poindexter N, Roth JA, Ramesh R, Grimm EA, Mhashilkar AM. mda-7/IL-24 is a unique cytokine-tumor suppressor in the IL-10 family. Int Immunopharmacol, 2004, 4: 649-667.

[5.] Su Z-Z, Madireddi MT, Lin JJ, Young CS, Kitada S, Reed JC, Goldstein NI, Fisher PB. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc Natl Acad Sci, 1998, 95: 14400-14405.

[6.] Ekmekcioglu S, Ellerhorst J, Mhashilkar AM, Sahin AA, Read CM, Prieto VG, Chada S, Grimm EA. Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int J Cancer, 2001, 94: 54-59.

[7.] Lebedeva IV, Sarkar D, Su Z-Z, Kitada S, Dent P, Stein C, Reed JC, Fisher PB. Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene, 2003, 22: 8758-8773.

[8.] Su Z, Emdad L, Sauane M, Lebedeva IV, Sarkar D, Gupta P, James CD, Randolph A, Valerie K, Walter MR. Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of mda-7/IL-24 protein by normal cells. Oncogene, 2005, 24: 7552-7566.

[9.] Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD, Sieger K, Mumm JB, Stewart AL, Boquio A, Dumoutier L. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res, 2003, 63: 5105-5113.

[10.] Dent P, Yacoub A, Grant S, Curie DT, Fisher PB. mda-7/IL-24 regulates proliferation, invasion and tumor cell radiosensitivity: a new cancer therapy?. J Cell Biochem, 2005, 95: 712-719.

[11.] Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther, 2005, 11: 160-172.

[12.] Azab B, Dash R, Das SK, Bhutia SK, Shen XN, Quinn BA, Sarkar S, Wang XY, Hedvat M, Dmitriev IP. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad. 5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells. J cell Physio, 2012, 227: 2145-2153.

[13.] Chen R. Bacterial expression systems for recombinant protein production: E. coli and beyond. Biotechnol Adv, 2012, 30: 1102-1107.

[14.] Ma Q, Jiang H, Liu K, Zhu J, Zheng X. Cloning of human interleukin 24 (mda-7/IL-24) gene and its fusion protein expression in E. coli. Jun Shi Yi Xue Ke Xue Yuan Yuan Kan, 2004, 28: 221-224.

[15.] Yang J, Zhang W, Liu K, Jing S, Guo G, Luo P, Zou Q. Expression, purification, and characterization of recombinant human interleukin 24 in Escherichia coli. Protein Expression Purif, 2007, 53: 339-345.

[16.] Liu J-J, Zhang B-F, Yin X-X, Pei D-S, Yang Z-X, Di J-H, Chen F-F, Li H-Z, Xu W, Wu Y-P. Expression, purification, and characterization of RGD-mda-7, a HIS-TAGGED mda-7/IL-24 mutant protein. J Immunoassay Immunochem, 2012, 33: 352-368.

[17.] Singh SM, Panda AK. Solubilization and refolding of bacterial inclusion body proteins. J Biosci Bioeng, 2005, 99: 303-310.

[18.] Petrides D, Cooney CL, Evans LB, Field RP, Snoswell M. Bioprocess simulation: an integrated approach to process development. Comput Chem Eng, 1989, 13: 553-561.

[19.] Kang H, Sun AY, Shen YL, Wei DZ. Refolding and structural characteristic of TRAIL/Apo2L inclusion bodies from different specific growth rates of recombinant Escherichia coli. Biotechnol Prog, 2007, 23: 286-292.

[20.] Chura-Chambi RM, Cordeiro Y, Malavasi NV, Lemke LS, Rodrigues D, Morganti L. An analysis of the factors that affect the dissociation of inclusion bodies and the refolding of endostatin under high pressure. Process Biochem, 2013, 48: 250-259.

[21.] Hayashi M, Iwamoto S, Sato S, Sudo S, Takagi M, Sakai H, Hayakawa T. Efficient production of recombinant cystatin C using a peptide-tag, 4AaCter, that facilitates formation of insoluble protein inclusion bodies in Escherichia coli. Protein Expression Purif, 2013, 88: 230-234.

[22.] Senthil K, Gautam P. Expression and single-step purification of mercury transporter (merT) from Cupriavidus metallidurans in E. coli. Biotechnol Lett, 2010, 32: 1663-1666.

[23.] Ferreira SC, Bruns R, Ferreira H, Matos G, David J, Brandao G, da Silva EP, Portugal L, Dos Reis P, Souza A. Box-Behnken design: an alternative for the optimization of analytical methods. Anal Chim Acta, 2007, 597: 179-186.

[24.] Mao X, Shen Y, Yang L, Chen S, Yang Y, Yang J, Zhu H, Deng Z, Wei D. Optimizing the medium compositions for accumulation of the novel FR-008/Candicidin derivatives CS101 by a mutant of Streptomyces sp. using statistical experimental methods. Process Biochem, 2007, 42: 878-883.

[25.] Singh SM, Upadhyay AK, Panda AK. Solubilization at high pH results in improved recovery of proteins from inclusion bodies of E. coli. J Chem Technol Biotechnol, 2008, 83: 1126-1134.

[26.] Patra AK, Mukhopadhyay R, Mukhija R, Krishnan A, Garg LC, Panda AK. Optimization of inclusion body solubilization and renaturation of recombinant human growth hormone from Escherichia coli. Protein Expression Purif, 2000, 18: 182-192.

[27.] Welinder C, Ekblad L. Coomassie staining as loading control in Western blot analysis. J Proteome Res, 2011, 10: 1416-1419.

[28.] Correa A, Oppezzo P. Tuning different expression parameters to achieve soluble recombinant proteins in E. coli: advantages of high-throughput screening. Biotechnol J, 2011, 6: 715-730.

[29.] Vincentelli R, Cimino A, Geerlof A, Kubo A, Satou Y, Cambillau C. High-throughput protein expression screening and purification in Escherichia coli. Methods, 2011, 55: 65-72.

[30.] Anderson MJ, Whitcomb PJ. RSM simplified: optimizing processes using response surface methods for design of experiments, 2005, Oxon: Productivity Press.

[31.] Xiao B, Li W, Yang J, Guo G, Mao XH, Zou QM. RGD-IL-24, a novel tumor-targeted fusion cytokine: expression, purification and functional evaluation. Mol Biotechnol, 2009, 41: 138-144.

[32.] Shivu B, Seshadri S, Li J, Oberg KA, Uversky VN, Fink AL. Distinct β-sheet structure in protein aggregates determined by ATR–FTIR spectroscopy. Biochemistry, 2013, 52: 5176-5183.

[33.] Shen YL, Xia XX, Zhang Y, Liu JW, Wei DZ, Yang SL. Refolding and purification of Apo2L/TRAIL produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli. Biotechnol Lett, 2003, 25: 2097-2101.